Drug Development and Emerging Therapies for Vascular Dementia

Despite its growing prevalence, vascular dementia has limited FDA-approved treatments. This session will explore promising drug candidates, including vasoactive drugs, anti-inflammatory agents, neuroprotective compounds, and anti-hypertensive therapies. Researchers will also present breakthroughs in clinical trials investigating stem cell therapy, gene therapy, and neurotrophic factors that promote brain repair. Attendees will gain insights into personalized medicine approaches, identifying which treatments work best for different vascular dementia subtypes. The session will also cover challenges in drug development, such as clinical trial design and patient recruitment. This session is highly relevant for pharmacologists, neuroscientists, and biotech industry professionals.

    Related Conference of Drug Development and Emerging Therapies for Vascular Dementia

    September 18-19, 2026

    21st Annual Congress on Neuroscience

    Dubai, UAE
    November 16-17, 2026

    8th World Brain Congress

    Tokyo, Japan
    November 23-24, 2026

    16th Global Alzheimers Summit

    Paris, France
    November 24-25, 2026

    38th World Conference on Neurology

    Rome, Italy
    December 16-17, 2026

    12th International Conference on Brain Injury & Neuro Surgeons

    Amsterdam, Netherlands
    December 21-22, 2026

    6th International Conference on Child Neurology

    Paris, France
    December 28-29, 2026

    18th Global Neurologists Meeting on Neurology and Neurosurgery

    Amsterdam, Netherlands
    December 28-29, 2026

    39th European Neurology Congress

    Amsterdam, Netherlands
    March 22-23, 2027

    8th International Conference on Neurologists

    Singapore City, Singapore
    March 24-25, 2027

    38th Conference on Clinical Neuroscience and Neurogenetics

    Geneva, Switzerland

    Drug Development and Emerging Therapies for Vascular Dementia Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in